Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 14Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Myelodysplastic Syndromes 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Basal Cell 3Burkitt Lymphoma 3Vulvar Neoplasms 2Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Seminoma 2Prostatic Neoplasms 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Urachal adenocarcinoma × CTLA-4 Antigen × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡